PDGFRA Amplification

CI-VAR-00000224Explore in graph →CIViC 716

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PDGFRA Amplification	Sunitinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID1771 In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression … (full text at CIViC) PMID 19366796 · McDermott et al., 2009 · Open in CIViC	civic
Lung Squamous Cell Carcinoma1
PDGFRA Amplification	Imatinib + SunitinibSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID7989 Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
PDGFRA Amplification	Trametinib	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID12457 Cell lines were treated with varying concentrations of trametinib for 3 days. Viability was measured by ATP-Glo. The lung large cell carcinoma cell line, H661 (PDGFRA amplification), was not sensitive… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic